SATURN: An exploration of the dynamic interaction between IL-17, IL-17 inhibition with (secukinumab) and neutrophils in psoriatic arthritis in vitro and ex vivo with exploratory study on the potential role of Vitamin D

Trial Profile

SATURN: An exploration of the dynamic interaction between IL-17, IL-17 inhibition with (secukinumab) and neutrophils in psoriatic arthritis in vitro and ex vivo with exploratory study on the potential role of Vitamin D

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Secukinumab (Primary) ; Leflunomide; Methotrexate; Sulfasalazine
  • Indications Psoriatic arthritis
  • Focus Pharmacodynamics
  • Acronyms SATURN
  • Sponsors Novartis
  • Most Recent Events

    • 22 May 2017 Control group has been removed from the study hence treatment arms has been decreases and patients number also decreases.
    • 22 May 2017 Planned number of patients changed from 30 to 20.
    • 14 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top